Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05358886
Other study ID # BPN14770-CNS-301
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date November 1, 2022
Est. completion date July 2024

Study information

Verified date February 2024
Source Tetra Discovery Partners
Contact CEO
Phone 616-224-0084
Email info@tetratherapeutics.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date July 2024
Est. primary completion date February 2024
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Male subject aged 18 to 45 years at screening visit. 2. Subject has FXS with a molecular genetic confirmation of the full fragile X mental retardation-1 (FMR1)mutation (=200 CGG repetitions). 3. Subject is able to swallow capsules. 4. Current treatment with =3 prescribed psychotropic medications. Anti-epileptic medications are permitted and are not counted as psychotropic medications if they are used for the treatment of seizures. Anti-epileptics for other indications, such as the treatment of mood disorders, count towards the limit of permitted medications. 5. Permitted concomitant psychotropic medications must be at a stable dose and dosing regimen for at least 4 weeks prior to screening and must remain stable during the period between screening and the commencement of the study treatment. 6. Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks prior to screening and must remain stable during the period between screening and commencement of the study treatment. 7. Subjects with a history of seizure disorder who are currently receiving treatment with anti-epileptics must have been seizure free for 3 months preceding screening or must be seizure free for 2 years if not currently receiving anti-epileptics. 8. Behavioral and other non-pharmacological treatments/interventions must be stable for 4 weeks prior to screening and must remain stable during the period between screening and first dose of study treatment and throughout the study. Minor changes in hours or times of therapy that are not considered clinically significant will not be exclusionary. Changes in therapies provided through a program (eg, due to a vacation) are allowed. 9. Subject must be willing to practice barrier methods of contraception while on the study if sexually active. Abstinence is also considered a reasonable form of birth control in this study population. 10. Subject has a parent, legal authorized guardian, or consistent caregiver. 11. Subject and caregiver are able to attend the clinic regularly and reliably. 12. If subject is his own legal guardian, he is able to understand and sign informed consent to participate in the study. 13. For subjects who are not their own legal guardian, subject's parent/legally authorized guardian is able to understand and sign an informed consent form for their child to participate in the study. 14. If subject is not his own legal guardian, subject must provide assent for participation in the study if he has the cognitive ability to do so. Exclusion Criteria: 1. Inability to successfully complete the NIH-TCB picture vocabulary and oral reading assessments at screening and baseline. The ability to complete the NIH-TBC oral reading and picture vocabulary subtest at baseline is defined as the ability to complete both subtests, with (1) confirmation from the clinician administering that the test administrations are valid (noted on the administration form) and (2) generation of valid test scores for each test. 2. History of or current cardiovascular, renal, hepatic, respiratory, gastrointestinal, psychiatric, neurologic, cerebrovascular, or other systemic disease that would place the subject at risk or potentially interfere with the interpretation of the safety, tolerability, or efficacy of the study treatment. a. Common conditions such as mild hypertension, etc. are allowed per the principal investigator's judgement as long as they are stable and controlled by medical therapy that is constant for at least 4 weeks before randomization. 3. Renal impairment, defined as serum creatinine > 1.25 × ULN at screening 4. Hepatic impairment, defined as ALT or AST elevation > 2 × ULN at screening. Note: LFTs may be repeated after 1 week to evaluate return to acceptable limits; if LFTs remain elevated, the subject is ineligible to participate. 5. Clinically significant abnormalities, in the investigator's judgement, in safety laboratory tests, vital signs, or ECG, as measured during screening. 6. History of substance abuse within the past year, according to investigator assessment. 7. Positive COVID-19 test during screening. 8. Significant hearing or visual impairment that may affect the subject's ability to complete the test procedures. 9. Concurrent major psychiatric condition (eg, major depressive disorder, schizophrenia, or bipolar disorder) as diagnosed by the investigator. Subjects with the additional diagnosis of autism spectrum disorder or anxiety disorder will be allowed. 10. Subject has active diseases that would interfere with participation, such as acquired immunodeficiency disorder, hepatitis C, hepatitis B, or tuberculosis. 11. Subject is planning to commence psychotherapy or cognitive behavior therapy during the period of the study or had begun psychotherapy or cognitive behavior therapy within 4 weeks prior to screening. 12. Subject is an immediate family member of anyone employed by the sponsor, investigator, or study staff. 13. Subject has a body mass index of less than 18 kg/m2 or greater than 36 kg/m2. 14. Subject has participated in another clinical trial within the 30 days preceding Screening

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BPN14770/ zatolmilast
25mg BID BPN14770
Placebo
Placebo

Locations

Country Name City State
United States Emory University School of Medicine Atlanta Georgia
United States Kennedy Krieger Institute Baltimore Maryland
United States Rush University Medical Center Chicago Illinois
United States Cincinnati Childrens Hospital Medical Center Cincinnati Ohio
United States Children's Hospital Colorado Denver Colorado
United States Amnova Clinical Research Irvine California
United States University of Kansas Medical Center Kansas City Kansas
United States Suburban Research Associates Media Pennsylvania
United States Icahn School of Medicine at Mount Sinai Hospital New York New York
United States CHOC Thompson Autism Center Orange California
United States UC Davis Health System Sacramento California
United States Clinic for Special Children Strasburg Pennsylvania
United States University of Massachusetts Medical School Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Tetra Discovery Partners

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary National Institutes of Health Toolbox Cognitive Battery cognition crystallized composite score (NIH-TCB CCC) National Institutes of Health Toolbox Cognitive Battery cognition crystallized composite score (NIH-TCB CCC), which is calculated from the Picture Vocabulary and Oral Reading domains. 13 Weeks
Secondary Numerical rating scale (NRS) scores based on subject-specific behaviors vs baseline Numerical rating scale (NRS) scores based on subject-specific behaviors within the domains of Daily Function and Language 13 Weeks
Secondary Caregiver Global Impression of Improvement (CaGI-I) Caregiver Global Impression of Improvement (CaGI-I) for the general domains of Daily Function and Language 13 Weeks
Secondary Clinical Global Impression Improvement (CGI-I) for - Investigator Clinical Global Impression Improvement (CGI-I) for - Investigator rated the general domains of Daily Function and Language 13 Weeks
Secondary Vineland-3 Adaptive Behavior Scale (Vineland-3) Vineland-3 Adaptive Behavior Scale (Vineland-3), using the composite score and domain scores from communication, daily living skills, and socialization 13 Weeks
Secondary Verbal Knowledge test from the Stanford-Binet (ed 5) (SB-5)IQ Verbal Knowledge test from the Stanford-Binet (ed 5) (SB-5) IQ assessment 13 Weeks
Secondary NIH-TCB domains of Picture Sequence Memory, Flanker Inhibitory Control and Attention, List Sorting Working Memory, Dimensional Change Card Sort, and Speeded Matching NIH-TCB domains of Picture Sequence Memory, Flanker Inhibitory Control and Attention, List Sorting Working Memory, Dimensional Change Card Sort, and Speeded Matching 13 Weeks
Secondary Aberrant Behavior Checklist (ABC) scores Aberrant Behavior Checklist (ABC) scores 13 Weeks
Secondary Anxiety, Depression, and Mood Scale (ADAMS) scores Anxiety, Depression, and Mood Scale (ADAMS) scores 13 Weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05418049 - Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge Phase 2
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Completed NCT00965432 - A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107 Phase 1
Completed NCT01120626 - Randomized Controlled Study of Donepezil in Fragile X Syndrome Phase 2
Completed NCT01204151 - Teaching Math Skills to Individuals With Fragile X Syndrome N/A
Active, not recruiting NCT00334971 - Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women N/A
Enrolling by invitation NCT06139172 - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities N/A
Recruiting NCT04977986 - Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome Phase 3
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Completed NCT03722290 - Metformin in Children and Adults With Fragile X Syndrome Phase 2
Completed NCT05030129 - Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome Phase 2
Recruiting NCT05957549 - Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG N/A
Recruiting NCT04141163 - Metformin in Patients With Fragile X Phase 1/Phase 2
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Completed NCT00858689 - Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Enrolling by invitation NCT03802799 - Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS Phase 2/Phase 3
Recruiting NCT05295277 - Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT01725152 - Ganaxolone Treatment in Children With Fragile X Syndrome Phase 2